Latest News

View allAccessAL amyloidosisCAR-TConferencesMPEMyelomaNewsPatient evidenceVideos

Highlights from the Myeloma Cure Summit

Myeloma has always been an incurable cancer which is becoming increasingly chronic with treatment advances and access. Whilst the community remains cautious talking about myeloma as a curable cancer there is optimism amongst industry experts.The Myeloma Cure Summit was an event organised by the International Myeloma Society in Miami, Florida, USA from 20 – 21 February 2026.…

Read more

The European Commission grants final authorisation for belantamab mafodotin (Blenrep®) combinations for relapsed/refractory myeloma patients

Two belantamab mafodotin (Blenrep®) combinations, with bortezomib and dexamethasone or pomalidomide and dexamethasone, are now authorised for use in the European Union. The decision follows an earlier positive recommendation of European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP – their scientific advisory committee) on 23 May 2025. Marketing authorisation means that…

Read more

New guidelines for the treatment and the management of myeloma and smouldering myeloma

On July 7th, 2025, new clinical management guidelines for myeloma and smouldering myeloma were published in Nature Reviews Clinical Oncology by myeloma experts. These guidelines are written to guide doctors and healthcare professionals in myeloma and smouldering myeloma diagnosis, treatment and follow-up, based on the most up-to-date scientific knowledge. The last treatment guidelines were published in…

Read more

MPE member spotlight: Multiple Myeloma Ireland

On May 23rd, MPE member organisation, Multiple Myeloma Ireland (MMI) successfully hosted its 2025 Patient and Family Information Day at the Ashling Hotel in Dublin. Multiple Myeloma Ireland is the only charitable organisation in Ireland focused exclusively on supporting patients, families and carers with myeloma and related conditions. As a valued member of Myeloma Patients Europe (MPE), MMI…

Read more

EMA CHMP gives positive opinion on linvoseltamab for relapsed/refractory myeloma patients

On 27th February 2025, the Committee for Medicinal Products for Human Use (CHMP) recommended the approval of linvoseltamab for the treatment of patients with relapsed/refractory multiple myeloma. The CHMP is the European Medicines Agency’s committee responsible for opinions on all issues regarding medicinal products for human use. Based on these opinions, then the European Commission…

Read more
March

April 2026

May
MO
TU
WE
TH
FR
SA
SU
30
31
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
1
2
3
Events for 1st April
No Events
Events for 2nd April
No Events
Events for 3rd April
No Events
Events for 4th April
No Events
Events for 5th April
No Events
Events for 6th April
No Events
Events for 7th April
No Events
Events for 8th April
No Events
Events for 9th April
No Events
Events for 10th April
No Events
Events for 11th April
No Events
Events for 12th April
No Events
Events for 13th April
No Events
Events for 14th April
No Events
Events for 15th April
No Events
Events for 16th April
No Events
Events for 17th April
No Events
Events for 18th April
No Events
Events for 19th April
No Events
Events for 20th April
No Events
Events for 21st April
No Events
Events for 22nd April
No Events
Events for 23rd April
No Events
Events for 24th April
No Events
Events for 25th April
No Events
Events for 26th April
No Events
Events for 27th April
No Events
Events for 28th April
No Events
Events for 29th April
No Events
Events for 30th April
No Events